Emmaus Life Sciences, Inc.
EMMA · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3 | $3 | $2 | $3 |
| % Growth | 19.9% | 17.1% | -26.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $3 | $3 | $2 | $3 |
| % Margin | 92.7% | 94.7% | 90.6% | 90.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $2 | $2 | $2 |
| SG&A Expenses | $2 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $3 | $4 |
| Operating Income | $1 | -$0 | -$1 | -$1 |
| % Margin | 20.6% | -13.1% | -40.7% | -16.9% |
| Other Income/Exp. Net | -$2 | -$1 | -$1 | -$1 |
| Pre-Tax Income | -$1 | -$2 | -$2 | -$2 |
| Tax Expense | $1 | -$1 | $0 | $0 |
| Net Income | -$2 | -$1 | -$2 | -$2 |
| % Margin | -61.5% | -40.3% | -96.8% | -53.1% |
| EPS | -0.03 | -0.018 | -0.037 | -0.027 |
| % Growth | -68.5% | 51.2% | -33.2% | – |
| EPS Diluted | -0.03 | -0.018 | -0.037 | -0.027 |
| Weighted Avg Shares Out | 64 | 64 | 64 | 64 |
| Weighted Avg Shares Out Dil | 64 | 64 | 64 | 64 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$0 |
| Interest Expense | $2 | $2 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$1 | -$0 |
| % Margin | 13.3% | -1.5% | -44.3% | -13.9% |